Navigation Links
AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
Date:7/8/2008

SAN MATEO, Calif., July 8 /PRNewswire/ -- After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry.

On July 3rd AlphaDetail launched its latest AlphaPulse(TM) survey to measure immediate physician awareness and reactions to the panel recommendation. In a brief on-line survey of 52 cardiologists and 51 endocrinologists AlphaDetail found:

-- Unaided, about 40% of physicians mentioned CV risk associated with

diabetes medications as the most important development in diabetes

treatment from the past month.

-- When prompted, half of physicians indicated they had heard about the

FDA panel recommendation to require cardiovascular safety trials for

new diabetes medications -- only a day after the news was announced.

-- Although most physicians from both specialties support the

recommendation, twice as many cardiologists (33%) vs. endocrinologists

(16%) agree strongly with it.

-- However, 22% of endocrinologists disagree with the

recommendation primarily because they believe it would stifle

innovation and delay the availability of important new

therapies.

-- Physicians disagree on the most appropriate implementation of the FDA

panel recommendation -- two CV safety trials vs. only one trial.

-- However, more physicians believe that the two trial

implementation is the most appropriate.

-- Even so, a segment of physicians (25% of cardiologists and 37% of

endocrinologists) would support prescribing a new diabetes therapy that

is highly efficacious but has CV risk to patients that have no CV risk

factors other than diabetes.

-- Physicians have to make a trade-off between controlling diabetes

and preventing other diabetes complications vs. preventing CV

risk.

To learn more about this study, please contact Bob Latshaw at Bob.Latshaw@alphadetail.com or (215) 259-5601.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us answer our client's most challenging questions.


'/>"/>
SOURCE AlphaDetail, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Physicians Reconsider Implications of Enhance Trial
6. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
7. ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
8. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
9. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
10. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
11. American Meat Institute Calls WCRF Panel Recommendations on Meat Consumption Extreme and Unfounded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... ... October 12, 2017 , ... In ... taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, ... overseas retirement havens have extremely low property-tax rates, which contributes to the relatively ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
Breaking Medicine News(10 mins):